Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Non-Current Deferred Tax Liability: 2020-2024

Historic Non-Current Deferred Tax Liability for Xeris Biopharma Holdings (XERS) over the last 3 years, with Dec 2024 value amounting to $6.1 million.

  • Xeris Biopharma Holdings' Non-Current Deferred Tax Liability fell 70.23% to $6.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was $6.1 million, marking a year-over-year decrease of 70.23%. This contributed to the annual value of $6.1 million for FY2024, which is 70.23% down from last year.
  • According to the latest figures from Q4 2024, Xeris Biopharma Holdings' Non-Current Deferred Tax Liability is $6.1 million, which was up 83.27% from $3.3 million recorded in Q2 2024.
  • Xeris Biopharma Holdings' Non-Current Deferred Tax Liability's 5-year high stood at $20.5 million during Q4 2023, with a 5-year trough of $442,000 in Q4 2020.
  • Moreover, its 3-year median value for Non-Current Deferred Tax Liability was $3.6 million (2022), whereas its average is $5.2 million.
  • As far as peak fluctuations go, Xeris Biopharma Holdings' Non-Current Deferred Tax Liability soared by 1,100.45% in 2021, and later tumbled by 70.23% in 2024.
  • Xeris Biopharma Holdings' Non-Current Deferred Tax Liability (Quarterly) stood at $442,000 in 2020, then skyrocketed by 1,100.45% to $5.3 million in 2021, then tumbled by 31.53% to $3.6 million in 2022, then soared by 463.31% to $20.5 million in 2023, then tumbled by 70.23% to $6.1 million in 2024.
  • Its last three reported values are $6.1 million in Q4 2024, $3.3 million for Q2 2024, and $2.6 million during Q1 2024.